Sorrento Therapeutics, Inc.
SRNE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SRNE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2023.
Tracking 1 pipeline candidate for Sorrento Therapeutics, Inc..
Run Sorrento Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sorrento Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
5.2 months
OCF -$56M · Net income -$95M
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 12.0%
- Days to cover
- 5.0
- Shares short
- 64,564,656
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SRNE short interestFrequently asked questions
What is Sorrento Therapeutics, Inc.'s lead drug candidate?
Sorrento Therapeutics, Inc.'s most advanced tracked candidate is semdexa (Phase 3) for Painful conditions (off-label corticosteroid epidural injection replacement).
Who is the CEO of Sorrento Therapeutics, Inc.?
Dr. Henry H. Ji Ph.D. is the chief executive officer of Sorrento Therapeutics, Inc. (SRNE).
Where is Sorrento Therapeutics, Inc. headquartered?
Sorrento Therapeutics, Inc. (SRNE) is headquartered in San Diego, CA, United States.
What therapeutic areas does Sorrento Therapeutics, Inc. focus on?
Sorrento Therapeutics, Inc. develops therapies across Oncology, Infectious Disease, Pain, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.